Trials / Completed
CompletedNCT03155412
Adipose Tissue Expandability and Type 2 Diabetes
Limited Adipose Tissue Expandability as a Risk Factor for Development of Type 2 Diabetes: the Role of Preadipocytes
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 44 (actual)
- Sponsor
- Charles University, Czech Republic · Academic / Other
- Sex
- Male
- Age
- 30 Years – 45 Years
- Healthy volunteers
- Accepted
Summary
The goal of the study is to analyze deviations in adipogenic potential and metabolic properties of preadipocytes in subjects with genetic predisposition to type 2 diabetes, and thus identify factors that underlie hypertrophic growth of adipose tissue associated with the development of this disease.
Detailed description
Adipose tissue (AT) expands in response to excessive energy intake by hyperplasia or hypertrophy. While hyperplasia is associated with preservation of insulin sensitivity, hypertrophic AT exerts a number of metabolic defects. The mechanisms by which hyperplasia is suppressed at the expense of AT hypertrophy remain unknown, but it is expected that the hypertrophy of adipocytes is primarily driven by insufficient recruitment and differentiation of available preadipocytes. The limitation of hyperplasia occurs already in non-obese healthy subjects who are genetically predisposed to Type 2 Diabetes. Using these and control subjects, the LIMEX project aims to analyze the mechanisms of AT expandability. The project will combine in vivo characterization of AT and in vitro studies on human preadipocytes derived from AT biopsies obtained during clinical study. In vitro, proliferation, adipogenesis and lipogenesis of adipose cells will be monitored and these properties will be related to the degree of AT hypertrophy in vivo, insulin sensitivity and genetic predisposition to metabolic complications.
Conditions
Timeline
- Start date
- 2016-01-01
- Primary completion
- 2018-03-01
- Completion
- 2019-01-01
- First posted
- 2017-05-16
- Last updated
- 2020-02-13
Locations
1 site across 1 country: Czechia
Source: ClinicalTrials.gov record NCT03155412. Inclusion in this directory is not an endorsement.